Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ADH1B | P00325 | 1/20 | 0.48 |
| ▸ | ADH1C | P00326 | 1/20 | 0.48 |
| ▸ | ADH1A | P07327 | 1/20 | 0.48 |
| ▸ | ADH7 | P40394 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7695939 | 0.85 | ALDH1A1 (0.66) | ALDH1A1L3MBTL1MAPK1KMT2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL8053510 | 0.84 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1MAPK1KMT2ASLC6A2 | |
| SCHEMBL8537413 | 0.83 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1MAPK1KMT2AHCAR2 | |
| SCHEMBL8190011 | 0.83 | TDP1 (0.54) | ALDH1A1L3MBTL1MAPK1HCAR2TDP1 | |
| SCHEMBL24673477 | 0.82 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1MAPK1KMT2AHCAR2 | |
| SCHEMBL8190924 | 0.82 | LMNA (0.57) | ALDH1A1KMT2ATDP1ADH1BADH1C | |
| SCHEMBL7721059 | 0.81 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1MAPK1KMT2AHCAR2 | |
| SCHEMBL12666269 | 0.81 | ADH1B (0.47) | ALDH1A1L3MBTL1MAPK1KMT2AHCAR2 | |
| SCHEMBL8610893 | 0.81 | EPHX2 (0.53) | ALDH1A1L3MBTL1MAPK1KMT2AHCAR2 | |
| SCHEMBL8615529 | 0.81 | HTT (0.52) | ALDH1A1L3MBTL1MAPK1KMT2AHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2004-09-30 | — | — | US | claimed |
| EP-0854723-B1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | SEARLE & CO (US) | 2003-04-23 | — | — | EP | claimed |
| EP-0923933-B1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | SEARLE & CO (US) | 2002-07-03 | — | — | EP | claimed |
| EP-0923933-A1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | G.D. SEARLE & CO. (US) | 1999-06-23 | — | — | EP | claimed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | claimed |
| US-5763437-A | Benzodiazepine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-09 | — | — | US | claimed |
| US-5756529-A | ANTIINFLAMMATORY | G.D. SEARLE & CO. (US) | 1998-05-26 | — | — | US | claimed |
| EP-0804425-A2 | BENZODIAZEPINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-05 | — | — | EP | claimed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | claimed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | claimed |
| WO-1996004254-A2 | BENZODIAZEPINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-15 | — | — | WO | claimed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | claimed |
| US-5250677-A | Anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-10-05 | — | — | US | claimed |
| US-5175283-A | Enzyme inhibitors for antitrypsin or antithrombin as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 1992-12-29 | — | — | US | claimed |
| US-5110812-A | Treatment of pancreatitis; anticoagulants | BRISTOL-MYERS SQUIBB CO. (US) | 1992-05-05 | — | — | US | claimed |
| US-5037819-A | Anticoagulant; treating pancreatitis | BRISTOL-MYERS SQUIBB COMPANY (US) | 1991-08-06 | — | — | US | claimed |
| CN-108025574-A | Thermal recording medium | 三光株式会社 | 2018-05-11 | — | — | CN | disclosed |
| US-RE44048-E1 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | G.D. SEARLE LLC (US) | 2013-03-05 | — | — | US | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| US-5037819-A | Anticoagulant; treating pancreatitis | BRISTOL-MYERS SQUIBB COMPANY (US) | 1991-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | IL6, HRH4, CCR2 | ALDH1A1 1964/4885L3MBTL1 2567/4885MAPK1 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.